The
following table presents the number of shares subject to outstanding stock options, warrants, and Series A convertible preferred stock
that were excluded from the computation of diluted net loss per share of common stock for the three months ended March 31, 2026 and 2025,
as their effect was anti-dilutive:
Schedule
of Securities Excluded from the Computation of Diluted Net Loss per Common Stock
| | |
2026 | | |
2025 | |
| | |
Three months ended March 31, | |
| | |
2026 | | |
2025 | |
| Stock options | |
| 20,997 | | |
| 11,880 | |
| Warrants | |
| 841,291 | | |
| 1,291 | |
| Preferred stock converted into common stock | |
| 1,049 | | |
| 181 | |
| RSUs | |
| - | | |
| 2 | |
| Total potential common shares excluded from computation | |
| 863,337 | | |
| 13,354 | |
|